Company news
Scancell Holdings Plc (LSE:SCLP) news
Scancell Holdings Plc news releases on 6ix. Latest, Nov 7, 2022: Licenses Vaccitech technology to advance Modi-2
Press releases — page 3
Licenses Vaccitech technology to advance Modi-2
November 7, 2022
First patient dosed in expansion phase of ModiFY
October 31, 2022
Results for the year ended 30 April 2022
October 28, 2022
Directorate Changes
October 26, 2022
Signs Commercial License Agreement with Genmab
October 25, 2022
Change of Nominated Adviser
October 13, 2022
Preclinical data at the EuroMAbNet Annual Meeting
September 23, 2022
Change of Registered Office
September 6, 2022
First patient dosed in Cohort 2 of the ModiFY
August 16, 2022
Scancell to produce TCB antibodies
June 23, 2022
Phase 2 SCOPE trial of SCIB1 vaccine expanded
June 15, 2022
First patient dosed in Modi-1 Phase 1 trial
June 13, 2022
Change of Registered Holder of Shares
April 12, 2022
Modi-1 Phase 1/2 trial open for recruitment
April 11, 2022
Update on COVIDITY clinical trial
March 29, 2022
Scancell progresses its new anti-glycan mAb
March 17, 2022
Update on COVIDITY Phase 1 clinical trial
January 31, 2022
Interim Results for the 6 months ended 31 Oct 2021
January 26, 2022
First patient dosed in SCIB1 Phase 2 trial
November 19, 2021
Notice of Annual General Meeting
November 1, 2021
Results for the year ended 30 April 2021
October 29, 2021
Extension of CLN Redemption Dates
October 28, 2021
New facilities at The Oxford Science Park
October 19, 2021
First subject dosed in COVIDITY clinical trial
October 5, 2021
PDMR dealing
September 9, 2021
Modi-1 Phase I/II CTA approved by MHRA
August 26, 2021
Scancell selects PharmaJet's Needle-free Systems
August 17, 2021
COVIDITY Phase 1 trial application in SA approved
July 29, 2021
Lindy Durrant appointed CEO of Scancell
July 28, 2021
COVIDITY trial planned in South Africa and UK
June 22, 2021
Appointment of Joint Broker
June 15, 2021
BLOCK LISTING SIX MONTHLY RETURN
February 16, 2021
Statement regarding share price movement
February 15, 2021
Update on SCIB2 clinical development partnership
February 3, 2021
Interim Results for the 6 months ended 31 Oct 2020
January 29, 2021
COVID-19 vaccine candidate selected
December 18, 2020
Results of Annual General Meeting
November 17, 2020
Appointment of CMO and Medical Director
November 17, 2020
Result of Adjourned General Meeting
November 5, 2020
Convertible Loan Notes & Total Voting Rights
November 2, 2020
Result of Open Offer and Adjournment of GM
October 29, 2020
Conversion of Convertible Loan Notes
October 26, 2020
Final Results for the year ended 30 April 2020
October 16, 2020
Posting of Circular
October 13, 2020
Proposed investment by Redmile and Open Offer
October 12, 2020
Collaboration to manufacture COVID-19 vaccine
October 2, 2020
Director Award of Share Options
September 4, 2020
Funds awarded by Innovate UK for COVID-19 vaccine
August 27, 2020
Results of General Meeting
August 11, 2020
Shareholder circular
July 23, 2020